Trials / Recruiting
RecruitingNCT05872347
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPH4336 Tablets | SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral. |
Timeline
- Start date
- 2023-09-19
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2023-05-24
- Last updated
- 2025-08-17
Locations
25 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05872347. Inclusion in this directory is not an endorsement.